Is CANF or CAPR more undervalued in 2026?

CirclFi compares Can-Fite Biopharma Ltd (CANF) and Capricor Therapeutics, Inc. (CAPR) using 13 institutional-grade valuation models. CANF has a Quality of Company score of 2.2/10 while CAPR scores 6.9/10.

Which is a better buy — CANF or CAPR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CANF and CAPR valuations compare?

CANF at $3.36 and CAPR at $29.11 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CANF vs CAPR Valuation Comparison 2026 — Intrinsic Value Analysis

CANF

Biotechnology

Can-Fite Biopharma Ltd

Quality

2.2

out of 10

Value Trap

SAFE

Price

$3.36

Last close

Models

9/13

Active

CAPR

Biotechnology

Capricor Therapeutics, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$29.11

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	CANF Fair Value	CANF Upside	CAPR Fair Value	CAPR Upside
Bayesian DCF	Intrinsic	$0.89	-73.5%	$6.67	-77.1%
Earnings Power Value	Intrinsic	—	—	$15.35	-56.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$2.83	-15.6%	$27.78	-4.6%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CANF vs CAPR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CANF vs CAPR — Which Stock Is More Undervalued?

CAPR scores higher with a 6.9/10 quality rating vs CANF's 2.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Can-Fite Biopharma Ltd (CANF) and Capricor Therapeutics, Inc. (CAPR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CANF currently trades at $3.36 with a QOC of 2.2/10, while CAPR trades at $29.11 with a QOC of 6.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).